2-(2,3-dihydro-1,4-benzodioxin-3-yl)-5-pyridin-4-yl-6-(trifluoromethyl)-1H-benzimidazole | 1162688-94-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(2,3-dihydro-1,4-benzodioxin-3-yl)-5-pyridin-4-yl-6-(trifluoromethyl)-1H-benzimidazole
• CAS: 1162688-94-9
• 化学式: C₂₁H₁₄F₃N₃O₂
• 分子量: 397.356
• InChiKey: JQYWHCXCJACQAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  29
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  60
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  5-bromo-2-(2,3-dihydro-1,4-benzodioxin-3-yl)-6-(trifluoromethyl)-1H-benzimidazole 、 吡啶-4-硼酸 在 bis-triphenylphosphine-palladium(II) chloride 、 sodium carbonate 作用下， 生成 2-(2,3-dihydro-1,4-benzodioxin-3-yl)-5-pyridin-4-yl-6-(trifluoromethyl)-1H-benzimidazole
  参考文献：
  名称：

  The development of benzimidazoles as selective rho kinase inhibitors

  摘要：

  Rho Kinase (ROCK) is a serine/threonine kinase whose inhibition could prove beneficial in numerous therapeutic areas. We have developed a promising class of ATP-competitive inhibitors based upon a benzimidazole scaffold, which show excellent potency toward ROCK (IC50 < 10 nM). This report details the optimization of selectivity for ROCK over other related kinases such as Protein kinase A (PKA). (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.124

文献信息

• BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS
  申请人：Feng Yangbo

  公开号：US20110052562A1

  公开（公告）日：2011-03-03

  Compounds useful as Rho kinase inhibitors according to formula IA or IB: wherein A, B, D, E, R 1 , R 2 and Ar 1 are as defined herein, and any tautomer, salt, stereoisomer, hydrate, solvent, or prodrug thereof, pharmaceutical compositions, methods of treatment, and synthetic methods are provided.

  提供公式IA或IB所示的有用的Rho激酶抑制剂化合物：其中A、B、D、E、R1、R2和Ar1的定义如本文所述，并提供任何互变异构体、盐、立体异构体、水合物、溶剂或前药，以及制药组合物、治疗方法和合成方法。
• [EN] BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS<br/>[FR] BENZIMIDAZOLES ET ANALOGUES COMME INHIBITEURS DE LA RHO-KINASE
  申请人：FENG YANGBO

  公开号：WO2009079011A1

  公开（公告）日：2009-06-25

  Compounds useful as Rho kinase inhibitors according to formula IA or IB: wherein A, B, D, E, R1, R2 and Ar1 are as defined herein, and any tautomer, salt, stereoisomer, hydrate, solvent, or prodrug thereof, pharmaceutical compositions, methods of treatment, and synthetic methods are provided.
• The development of benzimidazoles as selective rho kinase inhibitors
  作者：E. Hampton Sessions、Michael Smolinski、Bo Wang、Bozena Frackowiak、Sarwat Chowdhury、Yan Yin、Yen Ting Chen、Claudia Ruiz、Li Lin、Jennifer Pocas、Thomas Schröter、Michael D. Cameron、Philip LoGrasso、Yangbo Feng、Thomas D. Bannister

  DOI：10.1016/j.bmcl.2010.01.124

  日期：2010.3

  Rho Kinase (ROCK) is a serine/threonine kinase whose inhibition could prove beneficial in numerous therapeutic areas. We have developed a promising class of ATP-competitive inhibitors based upon a benzimidazole scaffold, which show excellent potency toward ROCK (IC50 < 10 nM). This report details the optimization of selectivity for ROCK over other related kinases such as Protein kinase A (PKA). (C) 2010 Elsevier Ltd. All rights reserved.